Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.
You may also be interested in...
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
Glaxo Taps Astex for Fragment-Based Discovery Deal Worth At Least $33 Mil.
Astex expects up to an additional $61 million in near-term milestones, and avoids the option-based structure that GlaxoSmithKline prefers.